Nanobiotix Announces Key Development Milestones for 2021

 

• Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021
• Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021
• The Company’s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned

https://www.businesswire.com/news/home/20210108005259/en/Nanobiotix-Announces-Key-Development-Milestones-for-2021-After-Successful-Nasdaq-Initial-Public-Offering